Understanding how TRIM56 helps fight HIV-1
Official title: Antiretroviral mechanisms of TRIM56
Funded at Boston Children's Hospital · NIH-11084884 · Data updated 2026-11-12
This study is looking at how a protein called TRIM56 helps fight the HIV virus, which causes AIDS, and aims to find new ways to improve treatments for people living with HIV.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Boston Children's Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | December 1, 2024 |
| Project end | November 30, 2027 |
| Funding year | 2025 |
| Award (this year) | $77,284 |
| NIH project number | 1F32AI189235-01 |
| Project ID | NIH-11084884 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals living with HIV-1 who are seeking new treatment options.
✕Less likely to help
Patients who are not infected with HIV-1 or those with other unrelated health conditions may not benefit from this research.
What this research studies
This research investigates the role of TRIM56, an innate immune effector, in restricting HIV-1, the virus that causes AIDS. The project aims to uncover the molecular mechanisms by which TRIM56 exerts its antiviral effects, focusing on its unique ability to interact with viral RNA. By exploring how TRIM56 binds to HIV-1 and affects viral stability and packaging, the research seeks to identify new therapeutic targets for HIV treatment. Patients may benefit from insights gained that could lead to more effective anti-HIV therapies.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for treating HIV-1, potentially improving outcomes for patients living with HIV/AIDS.
How similar studies have gone: Previous research has shown promise in understanding the antiviral mechanisms of innate immune effectors, suggesting that this approach could yield valuable insights.
Where this research is happening
-
Boston Children's Hospital
Boston, United States Active
Researchers
- Principal investigator: Parsons, Molly Frances — Boston Children's Hospital
- Study coordinator: Parsons, Molly Frances
Related research
Other NIH-funded projects on the same topics.
-
Targeting the brain’s fluid system to treat post-hemorrhagic hydrocephalus
This grant explores a new approach to treating post-hemorrhagic hydrocephalus by studying how the brain’s fluid system and immune cells manage CSF after a brain bleed.
-
National Spina Bifida Patient Registry at Boston Children’s Hospital
A patient-focused registry project at Boston Children’s Hospital will collect and study information from people with spina bifida to improve care and outcomes.
-
Severe Chronic Neutropenia Registry for Patients
A patient-facing registry that tracks severe chronic low neutrophil counts to improve understanding and care for people with this condition.
-
Severe Chronic Neutropenia Registry to Improve Care
A patient-focused registry gathers information from adults with severe chronic neutropenia to better understand infections, treatments, and outcomes over time.
-
Severe Chronic Neutropenia Registry: Finding Better Ways to Prevent Infections
A patient-focused registry at a leading hospital helps people with severe chronic neutropenia learn how the condition progresses and how treatments work over time.
-
Exploring epilepsy genes in zebrafish to understand human brain seizures
A study in zebrafish will model human epilepsy genes to help explain how certain brain mutations contribute to seizures.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.